Use of Immunomodulators and Biologics Before, During, and after Pregnancy

Inflammatory Bowel Diseases

Volumn 22, Issue 1, 2016, Pages 213-223

  McConnell, Ryan A ^a   Mahadevan, Uma ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

azathioprine; breast feeding; inflammatory bowel disease; infliximab; pregnancy

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; BIOLOGICAL PRODUCT; CYCLOSPORIN; IMMUNOMODULATING AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR;

ADVERSE OUTCOME; BREAST FEEDING; BREAST MILK; CONGENITAL MALFORMATION; DISEASE SEVERITY; DRUG SAFETY; FETUS RISK; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; LACTATION; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK REDUCTION; COMPLICATION; FEMALE; INFLAMMATORY BOWEL DISEASES; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS;

BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 84964660329     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000596     Document Type: Review

References (136)

1. Shivashankar R, Tremaine WJ, Harmsen SW, et al. Updated incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted Country, Minnesota (1970-2010). Paper presented at: ACG 2014 Annual Scientific Meeting; October 22, 2014. Philadelphia, PA.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
3. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7:e206-e213.
4. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140:1827-1837.
5. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-A biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145:1459-1463.
6. Ørding Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002;122:15-19.
7. Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:847-853.
8. Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: A mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15:720-725.
9. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1983;18:735-742.
10. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58:229-237.
11. Timmer A, Bauer A, Dignass A, et al. Sexual function in persons with inflammatory bowel disease: A survey with matched controls. Clin Gastroenterol Hepatol. 2007;5:87-94.
12. Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: A meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55:1575-1580.
13. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease - A population-based cohort study. Am J Obstet Gynecol. 1997;177:942-946.
14. Fonager K, Sørensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: A follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426-2430.
15. Nørgard B, Fonager K, Sørensen HT, et al. Birth outcomes of women with ulcerative colitis: A nationwide Danish cohort study. Am J Gastroenterol. 2000;95:3165-3170.
16. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: A population-based cohort study. Am J Gastroenterol. 2002;97:641-648.
17. Stephansson O, Larsson H, Pedersen L, et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509-515.
18. Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: A case-control study. Scand J Gastroenterol. 2010;45:1302-1306.
19. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795-801.
20. Getahun D, Fassett M, Longstreth G, et al. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014;34:435-440.
21. Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091-1098.
22. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830-837.
23. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: A large community-based study from Northern California. Gastroenterology. 2007;133:1106-1112.
24. Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237-241.
25. Nguyen GC, Boudreau H, Harris ML, et al. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2009;7:329-334.
26. Bröms G, Granath F, Linder M, et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol. 2012;10:1246-1252.
27. Morales M, Berney T, Jenny A, et al. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology. 2000;47:1595-1598.
28. Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in Crohn's disease. Scand J Gastroenterol. 1984;19:724-732.
29. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: A controlled study of late pregnancy outcome. Am J Obstet Gynecol. 1989;160:998-1001.
30. Nørgard B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: A regional Danish cohort study. Am J Gastroenterol. 2007;102:1947-1954.
31. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203-1209.
32. Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011;34:724-734.
33. Ban L, Tata LJ, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76-84.
34. Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21:469-474.
35. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut. 1984;25:52-56.
36. Katz JA, Pore G. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis. 2001;7:146-157.
37. Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210.
38. Abhyankar A, Ham M, Moss AC. Meta-analysis: The impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38: 460-466.
39. Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: A prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501-512.
40. Mahadevan U, Martin C, Sandler RS, et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy [abstract]. Gastroenterology. 2012;142(5 suppl 1):S149.
41. Nasef NA, Ferguson LR. Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res. 2012;160:65-83.
42. Julsgaard M, Nørgaard M, Hvas CL, et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease. Scand J Gastroenterol. 2014;49:958-966.
43. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [Federal Register Web site]. 2014. Available at: http://federalregister.gov/a/2014-28241. Accessed May 30, 2015.
44. Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92:551-563.
45. Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94:187-207.
46. Del Campo M, Kosaki K, Bennett FC, et al. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology. 1999;60:10-12.
47. Food and Drug Administration. Methotrexate injection, USP [Food and Drug Administration Access Data Web site]. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/011719s117lbl. pdf. Accessed May 30, 2015.
48. Martínez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27:678-684.
49. French AE, Koren G; Motherisk Team. Effect of methotrexate on male fertility. Can Fam Physician. 2003;49:577-578.
50. Beghin D, Cournot MP, Vauzelle C, et al. Paternal exposure to methotrexate and pregnancy outcomes. J Rheumatol. 2011;38:628-632.
51. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, et al. No evidence for an increased risk of adverse pregnancy outcome after paternal lowdose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014;53:757-763.
52. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240-261.
53. Saarikoski S, Seppälä M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gyncecol. 1973;115:1100-1106.
54. de Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol. 2006;101:1390-1392.
55. Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63:451-457.
56. Nørgard B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: A population-based cohort study. Aliment Pharmacol Ther. 2003;17:827-834.
57. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647-654.
58. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696-701.
59. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60:198-203.
60. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-A drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433-440.
61. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15-22.
62. Hutson JR, Matlow JN, Moretti ME, et al. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol. 2013;33:1-8.
63. Nørgard B, Pedersen L, Christensen LA, et al. Therapeutic drug use in women with Crohn's disease and birth outcomes: A Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406-1413.
64. Shim L, Eslick GD, Simring AA, et al. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis. 2011;5:234-238.
65. Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: The PIANO registry [abstract]. Gastroenterology. 2014;146(5 suppl 1):S1.
66. de Meij TG, Jharap B, Kneepkens CM, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:38-43.
67. Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology. 2001; 121:1048-1053.
68. Rajapakse RO, Korelitz BI, Zlatanic J, et al. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 2000;95:684-688.
69. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study. Gastroenterology. 2003;124:9-17.
70. Nørgard B, Pedersen L, Jacobsen J, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther. 2004;19: 679-685.
71. Teruel C, López-San Román A, Bermejo F, et al. Outcomes of pregnancies father by inflammatory bowel disease patients exposed to thiopurines. Am J Gastroenterol. 2010;105:2003-2008.
72. Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, et al. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol. 2012;34:364-369.
73. Ng SW, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014;89:355-360.
74. Paziana K, Del Monaco M, Cardonick E, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36:279-294.
75. Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis. Transplantation. 2001;71:1051-1055.
76. Dozois EJ, Wolff BG, Tremaine WJ, et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum. 2006;49:64-73.
77. Xu L, Han S, Liu Y, et al. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol. 2009;22:28-31.
78. Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2007;6:479-485.
79. Jain AB, Reyes J, Marcos A, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: A single center's experience update at 13 years. Transplantation. 2003;76:827-832.
80. Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64:559-565.
81. Armenti VT, Moritz MJ, Davison JM. Drug safety issues in pregnancy following transplantation and immunosuppression: effects and outcomes. Drug Saf. 1998;19:219-232.
82. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.
83. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of followup in the TREAT registry. Am J Gastroenterol. 2012;107:1409-1422.
84. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854.
85. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641.
86. Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363-373.
87. Jürgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis. 2010;16:1634-1636.
88. Mahadevan U, Vermeire S, Wolf DC, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from safety surveillance [abstract]. Gastroenterology. 2015;148(4 suppl 1):S858-S859.
89. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology. 2014;146:85-95.
90. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: A systematic review. BMC Med. 2013;11:174.
91. Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFa therapies are safe during pregnancy in women with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862-1869.
92. Pentikäinen V, Erkkilä K, Suomalainen L, et al. TNFalpha downregulates the Fas ligand and inhibits germ cell apoptosis in the human testis. J Clin Endocrinol Metab. 2001;86:4480-4488.
93. Suominen JS, Wang Y, Kaipia A, et al. Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol. 2004;151:629-640.
94. Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:395-399.
95. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-292.
96. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003; 21:3365-3369.
97. Kane SV, Acquah LA. Placental transport of immunoglobulins: A clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228-233.
98. Julsgaard M, Lisbet A, Christensen PR, et al. Adalimumab and infliximab levels in neonates (ERA Study) [abstract]. Gastroenterology. 2015; 148(4 suppl 1):S108.
99. Arsenescu R, Arsenescu V, de Villiers WJ. TNF-A and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol. 2011;106:559-562.
100. Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007; 58:138-149.
101. Mahadevan U, Martin C, Dubinsky M, et al. Exposure to anti-TNFa therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry [abstract]. Gastroenterology. 2014;146:S170.
102. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-1058.
103. Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20:495-501.
104. Johnsson A, Avlund S, Grosen A, et al. Chicken pox infection in a three months old infant exposed in utero to Adalimumab. J Crohns Colitis. 2013;7:e116-e117.
105. Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-605.
106. Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958.
107. Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223.
108. Zelinkova Z, van der Ent C, van Baalen O, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318-321.
109. Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014;12:1474-1481.
110. Hoentjen F, Haarhuis BJ, Drenth JP, et al. Elective switching from infliximab to adalimumab in stable Crohn's disease. Inflamm Bowel Dis. 2013;19:761-766.
111. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17:958-963.
112. Cristiano L, Friend S, Bozic C, et al. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry. Neurology. 2013;80:P02.127.
113. Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198-205.
114. Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy-effects on the neonatal immune system. Acta Neurol Scand. 2013;127:e1-e4.
115. Mahadevan U, Dubinsky M, Vermeire S, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease [abstract]. J Crohns Colitis. 2015;9(suppl 1):S361-S362.
116. Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6:105-107.
117. Schaufelberg BW, Horn E, Cather JC, et al. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program [abstract]. J Am Acad Dermatol. 2014;70(5 suppl 1):AB178.
118. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367:616-624.
119. Marren A, Chen Y, Frazler D, et al. Pregnancy outcomes in the tofacitinib RA safety database through April 2014 [abstract]. Arthritis Rheumatol. 2014;66:S840.
120. Meyers D. Breastfeeding and health outcomes. Breastfeed Med. 2009;4 (suppl 1):S13-S15.
121. Matro R, Martin CF, Wolf DC, et al. Detection of biologic agents in breast milk and implication for infection, growth and development in infants born to women with inflammatory bowel disease: results from the PIANO Registry [abstract]. Gastroenterology. 2015;148 (4 suppl 1):S141.
122. Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity. 2003;36:51-56.
123. Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978-980.
124. Gardiner SJ, Gearry RB, Roberts RL, et al. Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in motherinfant pairs. Br J Clin Pharmacol. 2006;62:454-456.
125. Moretti ME, Verjee Z, Ito S, et al. Breast-feeding during maternal use of azathioprine. Ann Pharmacother. 2006;40:2269-2272.
126. Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG. 2007;114:498-501.
127. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther. 2008;28:1209-1213.
128. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555-558.
129. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475-476.
130. Wolf D, Mahadevan U. Certolizumab pegol use in pregnancy: low levels detected in cord blood [abstract]. Arthritis Rheum. 2010;62 (suppl 10):718.
131. Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005;100:102-105.
132. Moffatt DC, Ilnyckyj A, Bernstein CN. A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol. 2009; 104:2517-2523.
133. Barclay AR, Russell RK, Wilson ML, et al. Systematic review: The role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr. 2009;155:421-426.
134. Mountifield R, Andrews JM, Bampton P. It IS worth the effort: patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session. J Crohns Colitis. 2014;8:796-801.
135. De Lima A, Zelnikova Z, van der Ent C, et al. Preconception care in IBD women leads to less disease relapses during pregnancy [abstract]. Gastroenterology. 2014;146:S444.
136. Gawron LM, Hammond C, Keefer L. Documentation of reproductive health counseling and contraception in women with inflammatory bowel diseases. Patient Educ Couns. 2014;94:134-137.